Sonoma Pharmaceuticals, Inc. cash flow to debt ratio of -467.10% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Sonoma Pharmaceuticals, Inc.'s free cash flow has decreased 2.36K% from $-168.00K last year to $-4.12M, signaling decreasing performance

Sonoma Pharmaceuticals, Inc.'s debt to equity ratio is 0.11, which means that the company's assets are healthy financed, signaling financial stability.

Sonoma Pharmaceuticals, Inc.'s debt has increased relative to shareholder equity from 0.07 last year to 0.11 today, signaling weakened financials

Sonoma Pharmaceuticals, Inc. has a net cash position, so leverage is healthy.

Interest expense is not separately reported in Sonoma Pharmaceuticals, Inc.'s latest filing, so interest coverage cannot be calculated.

Sonoma Pharmaceuticals, Inc.'s profit margin has increased (-57.31%) in the last year from -24.20% to -10.33%, signaling increasing performance

Sonoma Pharmaceuticals, Inc.'s short-term assets of $12.10M exceed its short-term liabilities of $4.83M

Sonoma Pharmaceuticals, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Sonoma Pharmaceuticals, Inc.'s return on equity of -53.56%, is lower than 15.00%, indicating bad performance

Sonoma Pharmaceuticals, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Sonoma Pharmaceuticals, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Sonoma Pharmaceuticals, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Sonoma Pharmaceuticals, Inc. has negative free cash flow, indicating cash burn

Sonoma Pharmaceuticals, Inc.'s yearly earnings has increased -8.16% since last year from $-3.46M to $-3.17M, signaling increasing performance

Sonoma Pharmaceuticals, Inc.'s yearly revenue has increased 36.68% since last year from $14.29M to $19.53M, signaling increasing performance

ROIC -9.68% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Sonoma Pharmaceuticals, Inc.'s 3-year revenue CAGR of 13.74% is positive, indicating growing revenue over the past 3 years

Sonoma Pharmaceuticals, Inc. had revenue growth in 3 out of 5 years, indicating consistent revenue performance

Sonoma Pharmaceuticals, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Sonoma Pharmaceuticals, Inc. is overvalued relative to its fair value price of 1.21 based on Discounted Cash Flow model

Sonoma Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Sonoma Pharmaceuticals, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Sonoma Pharmaceuticals, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Sonoma Pharmaceuticals, Inc. is overvalued relative to its fair value price of -32.80 based on Earnings Fair Value model

Sonoma Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Sonoma Pharmaceuticals, Inc. has a price-to-book ratio of 0.75x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Sonoma Pharmaceuticals, Inc. has a price-to-sales ratio of 0.23x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue